Open Access Highly Accessed Research article

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

Tjalke A Westra1*, Irina Stirbu-Wagner2, Sara Dorsman2, Eric D Tutuhatunewa1, Edwin L de Vrij1, Hans W Nijman3, Toos Daemen1, Jan C Wilschut1 and Maarten J Postma4

Author Affiliations

1 Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands

2 NIVEL Netherlands Institute of Health Service Research, Utrecht, The Netherlands

3 Gynecologist-oncologist, Department of Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

4 Health Economist, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands and Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

For all author emails, please log on.

BMC Infectious Diseases 2013, 13:75  doi:10.1186/1471-2334-13-75

Published: 7 February 2013

Additional files

Additional file 1:

HPV-type specific cervical cancer progression and regression 6 month progression rates.

Format: DOCX Size: 12KB Download file

Open Data